Advanced Glycation End Products Inhibitors Market Size, Share, and Industry Analysis, By Drug (Carnosine, Pyridoxine, Agmatine, Benfotiamine, Alpha Lipoic Acid, and Others), By Indication (Metabolic Diseases, Cardiovascular Diseases, Degenerative Diseases, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

Advanced glycation end products (AGEs) are the harmful molecules formed by the non-enzymatic reactions between the reducing sugars and the proteins/lipids or nucleic acids. This metabolic reaction is referred to as glycation. AGEs are produced inside the body as a result of normal metabolic processes, but the major source of AGEs is food.

AGEs are also known as glycotoxins. They are linked with receptors located on the blood vessels and several other organs that cause damage to the organ systems. AGEs activate the inflammatory and other destructive processes in the several systems of the body. High levels of circulating AGEs are also linked with diabetes, chronic kidney disease, Alzheimer's disease, bone health disorders, and many others.

Currently, not a single pharmaceutical product, an advanced glycation end product inhibitor, is approved for treating medical conditions associated with the formation of AGEs in the body. To treat the diseases linked with AGEs, several health supplements are available in the market and are suggested by healthcare professionals to inhibit the activity of AGEs in the body. Dietary supplements, including vitamins, can be considered as an effective treatment option to inhibit the formation of advanced glycation end products.

The COVID-19 pandemic positively impacted the global advanced glycation end-products inhibitors market in 2020. Dietary supplements, including vitamins, are considered an effective option to inhibit the formation of advanced glycation end products. A large section of the population, especially those suffering from various chronic diseases, consumed these supplements to reduce the risk of developing COVID-19 infection and enhance their immunity.

Segmentation

Key Insights

The following key insights are covered in the report:

• Analysis: Role of Advanced Glycation End Products Inhibitors in Chronic Diseases


• Pipeline Analysis by Key Players


• Key Industry Developments by Key Players


• Prevalence of Key Diseases by Key Countries, 2023


• Impact of COVID-19 on the Market

Analysis by Indication

Based on the indication, the market can be segmented into metabolic diseases, cardiovascular diseases, degenerative diseases, and others.

The metabolic diseases segment held a significant market share in 2023. The growth of the segment is attributed to the growing prevalence of metabolic diseases, such as diabetes mellitus, glycogen storage disease, fatty liver, and many others.

• For instance, as per the data provided by the University of Bristol in October 2023, the presence of metabolic syndrome increases the risk of myocardial infarction and stroke. The prevalence of metabolic syndrome is very common; nearly one in four adults in the U.K. is thought to have metabolic syndrome.

Furthermore, the cardiovascular diseases segment is anticipated to grow at a significant growth rate in the coming years. The segmental growth is mainly driven by the rising prevalence of cardiovascular diseases globally.  

• For instance, according to the WORLD HEART REPORT 2023, more than half a billion individuals globally were estimated to be affected by cardiovascular diseases by the end of 2021.

Moreover, the degenerative diseases segment held a considerable market share in 2023, mainly due to the rising incidence of Alzheimer's and Parkinson's globally and also due to the heightened awareness regarding these diseases.

Regional Analysis

Based on the region, the advanced glycation end products inhibitors market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant market share in 2023 and is expected to exhibit a substantial CAGR during the forecast period. Market growth in the region is mainly due to the growing prevalence of cardiovascular diseases, metabolic diseases, degenerative diseases, and many others, which are linked with the advanced glycation end products.

• For example, as per the data provided by the American Heart Association, Inc., in January 2024, nearly 127.9 million Americans were living with cardiovascular diseases (CVD), including heart failure, coronary heart disease, stroke, or hypertension.

Furthermore, Europe accounted for a substantial market share in 2023 and is expected to grow at a considerable market share from 2024-2032. The robust intake of dietary supplements among European countries is one of the factors contributing to the market growth during the forecast period.

• For instance, as per the data provided by the National Center for Biotechnology Information (NCBI) in December 2023, dietary supplements have seen a sharp increase in terms of use and popularity in recent years amongst European nations. The same study stated that more than half of the adult population of Finland and Denmark were dietary supplement users. Also, 47.0% and 42.0% of the population of Switzerland and the Netherlands included dietary supplements in their daily diet.

Key Players Covered

The report includes the profiles of key players, such as Country Life Vitamins, Life Extension, Nutricost, BrexHealth, and HealthyHey Nutrition.

Key Industry Developments

• In February 2024, Country Life Vitamins announced the launch of a new product line of supplements, including anti-glycation products and antioxidants.


• In October 2023, Force Factor, LLC., introduced a new line of nutritional supplements to expand its product offerings in the global market.


• In August 2023, Lion Equity Partners announced the acquisition of Country Life Vitamins. This acquisition expanded the supplementary product portfolio of Lion Equity Partners.